Talal Warsi, MD (@docwarsi) header
Talal Warsi, MD (@docwarsi) profile picture

NHS doctor | Cardiology and AI research Real numbers, for trainees and the curious I build teaching tools ECG simulator | https://teapaw.org/t.co/OXyi8TcgSd

United Kingdom
Joined December 2015
Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)Photo by Talal Warsi, MD (@docwarsi)
ECGs are one of those essential skills that take many years to develop a deep physiological understanding of and intuition for. That's why @claudeai and I have built Dipole. A free 3D simulator and atlas for medical residents to do just that, faster. dipoleecg.com
2
2
1
56
283,342
Talal Warsi, MD retweeted
Over the past week, I’ve been overwhelmed by the love and support of friends, industry colleagues, and people I've never met. Thank you to everyone who has shown kindness to my family and me. It means the world to me. I came to the United States 53 years ago, and becoming an American citizen is one of the greatest gifts and proudest moments of my life. NVIDIA has been my life’s work. Building it into the company it is today alongside my colleagues has been a privilege and an honor. Nowhere but in America could a company like NVIDIA be possible. I love our country, and I love NVIDIA. I did not live up to the standards expected of everyone at NVIDIA, and I have made serious mistakes in my personal life. I created problems for the Board that I deeply regret. I own my mistakes completely, and I am committed to cooperating with the Board’s independent investigation. Since my departure, I’ve seen an outpouring of calls from NVIDIA’s employees, investors, business partners, and customers for me to return as CEO. Many continue to reach out to me directly as the company navigates complex technology, market, competitive, and geopolitical dynamics. NVIDIA is a once-in-a-generation company. If the Board of Directors decides that my return is in the best interest of our shareholders, our employees, the company, and America, I would be honored to answer these calls and return as CEO. Thank you again to everyone who has shared their good wishes. I am profoundly humbled by your support. To my family: I love you, and I will spend the rest of my life being worthy of yours. Jensen
58,760
119,612
24,178
1,143,618
54,217,500
Two CAMEO-SEMA papers worth reading together Invasive: exercise PAWP -10.6 mmHg vs placebo CMR substudy (n=49): LA reservoir strain +5.7% (95% CI +0.3 to +9.7), lower LV mass Small, mechanistic, no hard outcomes, but a coherent picture of unloading in obesity-related HFpEF
2
44
I wonder if a dermatologist led this study 👀
The authors analyze the degree to which clinical specialties are shielded from, or threatened by, AI depending on how much of their work requires in-person physical interaction. Learn more: nejm.ai/3UDkrIv
96
SYNCHRONIZE-CVOT did its job, Survodutide was noninferior for MACE The story is tolerability, about 1 in 5 on either dose stopped for GI effects vs 1.9% on placebo, most during dose escalation Rigid titration might be the real side effect? SYNCHRONIZE-START might make it clear
1
42
The OPTIMAL trials Two trials, same targets (<120 vs <140), same ~13 mmHg gap achieved in BP After stroke/TIA, HR 0.79 (0.67-0.94) In diabetes, HR 0.90 (0.77-1.06) The diabetes trial had half the event rate, and its CI still holds 0.79. Maybe BP targets should follow risk, not diagnosis.
30
Excellent commentary by @drjohnm on OptimPacing, why a number doesn't tell the whole story
Few are bigger evangelists for conduction system pacing than me But. But… These results—despite NEJM publication—do not settle the RV vs LBB pacing. I wrote about it here: medscape.com/viewarticle/bes…
1
1
3
968
What the biggest medical breakthroughs will be according to @Claude Fable 5.2. Realistic?
Introducing Claude Fable 5.2 and Claude Mythos 5.2, designed to tackle the most daunting technical challenges. They’re capable collaborators on ambitious projects in many fields, and show improvements in areas like coding, reasoning, and vision.
2
2
96
One iron infusion moved peak VO2 IN HFpEF by 1.1ml/kg/min vs placebo, plus 41m on the walk test. Haemoglobin up 1.4g/dL with peak HR unchanged, looks like more oxygen carried, not necessarily a fitter heart, which should matter for who gets it
IRONMET-HFpEF trial: one infusion of ferric derisomaltose was well tolerated and improved peak oxygen uptake at 12 weeks in iron-deficient patients with HFpEF, demonstrating evidence of improved exercise capacity. Download slides here: clinicaltrialresults.org/wp-…
1
52
Can't wait to redo my tables
Introducing Claude Fable 5.2 and Claude Mythos 5.2, designed to tackle the most daunting technical challenges. They’re capable collaborators on ambitious projects in many fields, and show improvements in areas like coding, reasoning, and vision.
36
They're calling it the greatest opening paragraph of any recent oncology article
4
267
AI tools don't just invent references. They give you real papers with someone else's PMID, or a real trial attached to a number it never reported. I built a free tool that checks every reference against PubMed, CrossRef and 3 other databases. github.com/WarsiMD/citation-…
2
2
76
Four skills in one, all designed to find and verify what you need and never ship anything without you verifying.
1
43
Free and open source (MIT)
10
Four skills in one:
2
ADAPT AF-DES The bleeding result is convincing major bleeding 10.6% vs 22.0% The one number I'd watch is ischaemic stroke, 8 vs 3 events (HR 2.64, CI 0.70–9.97), probably noise with numbers that small Still, it's getting hard to justify routine dual therapy at 1 year +
Presented at #TCT2026: In patients with atrial fibrillation and a stent placed at least 1 year earlier, non–vitamin K antagonist oral anticoagulant monotherapy resulted in fewer net adverse clinical events at 2 years than a NOAC plus clopidogrel. Full ADAPT AF-DES trial results: nej.md/4yOOTgK @crfheart
1
1
63
SIMPLAAFY in JAMA What to give after an uncomplicated LAA closure, 1857 patients randomised to 3 regimens Death, stroke, systemic embolism or major bleeding at 6 months was 6.9% with DAPT, 5.1% with reduced-dose NOAC and 3.3% with aspirin alone
1
60
Both simpler options were noninferior to DAPT Major bleeding was 4.5%, 2.7% and 1.7%, and 45-day device-related thrombus 3.4%, 0.9% and 2.7%. Both are exploratory, so I wouldn't read them as proven differences US-only, open-label, 6-month follow-up
1
1
44
PROGRESS in NEJM TAVR vs clinical surveillance in moderate aortic stenosis with at-risk features, 744 patients Death or heart-failure event at 2 years was 16.7% with TAVR vs 23.9% with surveillance (risk difference −7.2 points, 95% CI −13.1 to −1.3)
1
55
That's about 1 event avoided per 14 treated over 2 years All-cause death was 8.4% vs 7.3%. The gap comes from heart-failure events, 10.8% vs 19.0% Open-label, mean age 78, transfemoral balloon-expandable valve only, Edwards-funded
1
36
I think the real comparison is TAVR now vs replacement later, since 57.4% of the surveillance group had one within 2 years anyway Would this change how often you re-echo and refer moderate AS once symptoms or LV changes appear? doi.org/10.1056/NEJMoa260732…
9